Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors Clinical Trial

Official title:
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Status Recruiting

Clinical Trial Summary

This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

Clinical Trial Description

Preclinical studies have confirmed that the combination of T601 and 5-FC can not only enhance the anti-tumor effect, but also reduce the toxicity of T601. Considering the risks and benefits of participants of the clinical trial, the protocol design is divided into 4 parts: Part 1: dose-escalation study of single-dose of T601 to evaluate the safety and tolerability of T601 and to determine the MTD; Part 2: dose-escalation study of single-dose of T601 combined with predrug 5-FC, to evaluate the safety and tolerability of the treatment of single dose of T601 combined with predrug 5-FC and to determine the MTD of single dose of T601 when combing with 5-FC; Part 3: dose-escalation study of multiple-dose of T601 combined with predrug 5-FC, to explore the safety and tolerability of the treatment of multiple dose of T601 combined with predrug 5-FC and to determine the MTD of multiple dose of T601 when combing with 5-FC, also to determine the RP2D (recommended dose for Phase II Trial); Part 4: extending study of multiple-dose of T601 combined with predrug 5-FC, to evaluate the efficacy of the treatment of multiple-dose of T601 combined with predrug 5-FC in patients with various specific tumors and to evaluate the ORR, DCR and PFS according to the RECIST v1.1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04226066
Study type	Interventional
Source	Tasly Tianjin Biopharmaceutical Co., Ltd.
Contact	Xiaomin WANG, master
Phone	+86 22 8634 2163
Email	tsl-wangxiaomin@tasly.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 20, 2019
Completion date	May 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00728468` - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Completed	`NCT00768469` - Study Evaluating Safety And Tolerability, Solid Tumor	Phase 1
Recruiting	`NCT04908046` - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06231550` - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors	Phase 1
Not yet recruiting	`NCT05383703` - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor	Phase 1
Recruiting	`NCT05773937` - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT04328506` - Bioequivalency Study of CM082 Tablet in Healthy Volunteers	Phase 1
Recruiting	`NCT05886374` - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT00958724` - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT05949775` - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors	N/A
Terminated	`NCT02045095` - A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors	Phase 1
Completed	`NCT00884845` - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT05277454` - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT	Phase 1
Active, not recruiting	`NCT03792958` - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors	Phase 1
Withdrawn	`NCT00997360` - Study of PKI-179 Administered Orally to Subjects With Solid Tumors	Phase 1
Completed	`NCT04126668` - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers	Phase 1
Recruiting	`NCT05338957` - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.	Phase 1/Phase 2
Recruiting	`NCT03047811` - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors	N/A
Not yet recruiting	`NCT05478785` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors	Phase 1/Phase 2